SEARCH

SEARCH BY CITATION

References

  • 1
    Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 24652.
  • 2
    Millar WJ. Use of alternative health care practitioners by Canadians. Can J Public Health 1997; 88: 1548.
  • 3
    Panel on Definition and Description, CAM Research Methodology Conference, April 1995. Defining and describing complementary and alternative medicine. Altern Ther Health Med 1995; 3: 4957.
  • 4
    Office of Alternative Medicine. Classification of alternative medicine practices [web page]. http://altmed.od.nih.gov/oam/what-is-cam/classify.shtml. National Institutes of Health Office of Alternative Medicine [accessed 1998].
  • 5
    Northcott HC. Alternative Health Care in Canada. In: BolariaBS, DickinsonHD, Eds. Health, Illness, and Health Care in Canada. Toronto: Harcourt, Brace & Co., 1994: 487503.
  • 6
    Verhoef MJ, Sutherland LR. Outpatient health care utilization of patients with inflammatory bowel disease. Dig Dis Sci 1990; 35: 127680.
  • 7
    Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res 1996; 40: 5039.
  • 8
    Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 697701.
    Direct Link:
  • 9
    Hilsden RJ, Dunn C, Patten S, Scott CM, Verhoef MJ. Information needs and seeking behaviors of patients with inflammatory bowel disease. Gastroenterology 1998; 114: A995.
  • 10
    Aakster CW. Concepts in alternative medicine. Soc Sci Med 1986; 22: 26573.
  • 11
    Micozzi MS. Characteristics of complementary and alternative medicine. In: MicozziS, Ed. Fundamentals of complementary and alternative medicine. New York: Churchill Livingstone, 1996: 38.
  • 12
    The American Society of Clinical Oncology. The physician and unorthodox cancer therapies. J Clin Oncol 1997; 15: 4016.
  • 13
    Kienle GS, Kiene H. Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Altern Ther Health Med 1996; 2: 3954.
  • 14
    Kiene H. A critique of the double-blind clinical trial. Part 1. Altern Ther Health Med 1996; 2: 7480.
  • 15
    Friedman LM, Furberg CD, De Mets DL. Introduction to Clinical Trials. In: Fundamentals of Clinical Trials. 3rd ed. St. Louis: Mosby, 1996: 115.
  • 16
    Feagan BG, McDonald JW, Koval JJ. Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. Gastroenterology 1996; 110: 27583.
  • 17
    Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 185458.
  • 18
    Lindahl O, Lindwall L. Is all therapy just a placebo effect? Meta-medicine 1982; 3: 25559.
  • 19
    Penick SB, Fisher S. Drug-set interaction: psychological and physiological effects of epinephrine under differential expectations. Psychosom Med 1965; 27: 17782.
  • 20
    Kiene H. A critique of the double-blind clinical trial. Part 2. Altern Ther Health Med 1996; 2: 5964.
  • 21
    Aldridge D. Single case research designs. In: LewithGT, AldridgeD, Eds. Clinical research methodology for complementary therapies. London: Hodder & Stoughton, 1993: 13668.
  • 22
    Kiene H, von Schon-Angerer T. Single-case causality assessment as a basis for clinical judgment. Altern Ther Health Med 1998; 4: 417.
  • 23
    Lukoff D, Edwards D, Miller M. The case study as a scientific method for researching alternative therapies. Altern Ther Health Med 1998; 4: 4452.
  • 24
    Vickers A, Cassileth B, Ernst E, et al. How should we research unconventional therapies? Int J Technol Assess Health Care 1997; 13: 11121.
  • 25
    Kaegi E and the Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. Unconventional therapies for cancer: 1. Essiac. CMAJ 1998; 158: 897902.
  • 26
    Sadoval M, Mannick EE, Mishra J, Sadowska-Krowicka H, Clark DA, Miller MJS. Cat's claw (Uncaria tomentosa) protects against oxidative stress and indomethacin-induced intestinal inflammation. Gastroenterology 1997; 112: A1081.
  • 27
    Oh TY, Hahm KB, Lee KJ, Ahn BO, Kim WB, Yang J, Kim JH, Cho SW. Beneficial effects of DA-9601, extract of Artemisia asiatica, TNB-induced experimental colitis in the rat. Gastroenterology 1997; 112: A1054.
  • 28
    Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, et al. Randomized clinical trial of Plantago ovata efficacy as compared to mesalazine in maintaining remission in ulcerative colitis. Gastroenterology 1997; 112: A971.
  • 29
    McEwen LM. A double-blind controlled trial of enzyme potentiated hyposensitization for the treatment of ulcerative colitis. Clinical Ecology 1987; 5: 4751.
  • 30
    Zhi-shui C, Zhi-wei N, Qi-Li SU-Yao, Ming D. A clinical study in treating intractable ulcerative colitis with Traditional Chinese Medicine. Alternative Medicine Journal 1995; 3641.
  • 31
    Bihui W, Shunping R, Wujin F, Zhizhong Z, Changlin Q. Kui Jie Qing in the treatment of chronic non-specific ulcerative colitis. J Tradit Chin Med 1997; 17: 1013.
  • 32
    Zhongyin C. Treatment of ulcerative colitis with acupuncture. J Tradit Chin Med 1995; 15: 23133.